Q2 FY2026 EarningsFY26 Q2 results beat consensus on EPS and net loss despite high clinical spending. Net loss of $30.2M ($0.43/share) was narrower than the expected $32.4M ($0.47/share). Revenue remained at zero as expected for this clinical-stage biotech. The company announced a 50% workforce reduction to preserve a strong $285M cash position, extending its runway for the planned BLA filing of detalimogene in 2H 2026.
Financial report interval: 2026.01.30 - 2026.04.30
Overview: enGene Therapeutics(ENGN) the Revenue is 0 (--%), Meet estimate;the EBIT is -31.97 M (-17.86%), Beat estimate;the EPS is -0.43 (+15.69%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B--
0.00B--
0.00B--%
EBITExceed expectations
-0.03B17.86%
-0.03B20.49%
+0.00B2.63%
EPSExceed expectations
-0.4315.69%
-0.47367.13%
+0.04368.56%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf